文献速递心脑血管急症重症综合管理与镇静镇痛

高渗盐水与其他降颅内压药物用于急性创伤性脑损伤患者的系统评价与Meta分析

Hypertonic Saline Versus Other Intracranial-Pressure-Lowering Agents for Patients with Acute Traumatic Brain Injury: A Systematic Review and Meta-analysis.
PubMed 文献 · Neurocrit Care · 2023-06-28
一句话结论在急性TBI患者中,高渗盐水与其他降颅内压药物相比,6个月GOS评分、全因死亡率和总住院时间均无显著差异,但高渗盐水与不良性高钠血症相关(RR 2.13)。

该系统评价与Meta分析检索2000年以来所有年龄TBI患者中比较高渗盐水与其他降颅内压药物的RCT,共纳入10项RCT(760例患者),其中6项进入定量分析。主要终点6个月GOS评分(有利 vs 不利)在高渗盐水与其他药物间无显著差异(RR 0.82,95%CI 0.48-1.40;n=406;2项RCT)。全因死亡率(RR 0.96,95%CI 0.60-1.55;n=486;5项RCT)和总住院时间(RR 2.36,95%CI -0.53至5.25;n=89;3项RCT)亦无显著差异。高渗盐水与不良性高钠血症相关(RR 2.13,95%CI 1.09-4.17;n=386;2项RCT);未控制颅内压的降低在高渗盐水组有点估计优势,但未达统计学显著(RR 0.52,95%CI 0.26-1.04;n=423;3项RCT)。多数纳入RCT因缺乏盲法、结局数据不完整和选择性报告而存在不明确或高偏倚风险;证据确定性低至极低。

要点

  • 在急性TBI患者中,高渗盐水与其他降颅内压药物相比,6个月GOS评分(有利 vs 不利)无显著差异:RR 0.82(95%CI 0.48-1.40;n=406;2项RCT)。
  • 高渗盐水与不良性高钠血症风险增加相关:RR 2.13(95%CI 1.09-4.17;n=386;2项RCT)。
  • 全因死亡率无显著差异:RR 0.96(95%CI 0.60-1.55;n=486;5项RCT);总住院时间无显著差异:RR 2.36(95%CI -0.53至5.25;n=89;3项RCT)。
  • 未控制颅内压在高渗盐水组有点估计优势但未达统计学显著:RR 0.52(95%CI 0.26-1.04;n=423;3项RCT)。
  • 多数纳入RCT存在不明确或高偏倚风险(缺乏盲法、结局数据不完整、选择性报告),证据确定性低至极低。

适用人群与场景

  • 所有年龄的创伤性脑损伤(TBI)患者,来自纳入的随机对照试验。
  • 中重度急性TBI需降低颅内压(ICP)的患者。

研究设计与关键结果

  • 研究类型:系统评价与Meta分析(PROSPERO CRD42022324370),检索2000年以来比较高渗盐水与其他降颅内压药物的RCT,纳入10项RCT(760例患者),其中6项进入定量分析。
  • 主要终点:6个月GOS评分(有利 vs 不利)在高渗盐水与其他药物间无显著差异(RR 0.82,95%CI 0.48-1.40;n=406;2项RCT)。
  • 全因死亡率无显著差异:RR 0.96(95%CI 0.60-1.55;n=486;5项RCT)。
  • 总住院时间无显著差异:RR 2.36(95%CI -0.53至5.25;n=89;3项RCT)。
  • 高渗盐水与不良性高钠血症相关:RR 2.13(95%CI 1.09-4.17;n=386;2项RCT)。
  • 未控制ICP在高渗盐水组有点估计优势但未达统计学显著:RR 0.52(95%CI 0.26-1.04;n=423;3项RCT)。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入的多数RCT因缺乏盲法、结局数据不完整和选择性报告而存在不明确或高偏倚风险。
  • 证据确定性:低至极低。
  • 局限:原文指出正在进行中的RCT可能有助于减少这种不确定性;GOS评分报告的异质性反映了需要标准化的TBI核心结局集。

对床旁实践的改变

  • 原文结论认为,高渗盐水对临床重要结局无影响证据,且与不良性高钠血症相关;证据确定性低至极低,正在进行中的RCT可能有助于减少不确定性;GOS评分报告的异质性提示需要标准化的TBI核心结局集。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Acute traumatic brain injury (TBI) is a major cause of mortality and disability worldwide. Intracranial pressure (ICP)-lowering is a critical management priority in patients with moderate to severe acute TBI. We aimed to evaluate the clinical efficacy and safety of hypertonic saline (HTS) versus other ICP-lowering agents in patients with TBI. We conducted a systematic search from 2000 onward for randomized controlled trials (RCTs) comparing HTS vs. other ICP-lowering agents in patients with TBI of all ages. The primary outcome was the Glasgow Outcome Scale (GOS) score at 6 months (PROSPERO CRD42022324370). Ten RCTs (760 patients) were included. Six RCTs were included in the quantitative analysis. There was no evidence of an effect of HTS on the GOS score (favorable vs. unfavorable) compared with other agents (risk ratio [RR] 0.82, 95% confidence interval [CI] 0.48-1.40; n = 406; 2 RCTs). There was no evidence of an effect of HTS on all-cause mortality (RR 0.96, 95% CI 0.60-1.55; n = 486; 5 RCTs) or total length of stay (RR 2.36, 95% CI - 0.53 to 5.25; n = 89; 3 RCTs). HTS was associated with adverse hypernatremia compared with other agents (RR 2.13, 95% CI 1.09-4.17; n = 386; 2 RCTs). The point estimate favored a reduction in uncontrolled ICP with HTS, but this was not statistically significant (RR 0.52, 95% CI 0.26-1.04; n = 423; 3 RCTs). Most included RCTs were at unclear or high risk of bias because of lack of blinding, incomplete outcome data, and selective reporting. We found no evidence of an effect of HTS on clinically important outcomes and that HTS is associated with adverse hypernatremia. The included evidence was of low to very low certainty, but ongoing RCTs may help to the reduce this uncertainty. In addition, heterogeneity in GOS score reporting reflects the need for a standardized TBI core outcome set.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Bernhardt K, McClune W, Rowland MJ, et al. Hypertonic Saline Versus Other Intracranial-Pressure-Lowering Agents for Patients with Acute Traumatic Brain Injury: A Systematic Review and Meta-analysis. Neurocrit Care. 2023. PMID: 37380894. doi:10.1007/s12028-023-01771-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。